-+ 0.00%
-+ 0.00%
-+ 0.00%

GT Biopharma Swings to Q3 Net Loss of $3.5 Million

PUBT·11/16/2026 12:08:01
Listen to the news
GT Biopharma Swings to Q3 Net Loss of $3.5 Million
  • GT Biopharma swung to a third-quarter 2026 net loss of approximately $3.5 million from year-earlier net income of $8.3 million.
  • Research and development expenses more than doubled to approximately $1.7 million year over year, primarily due to higher material costs.
  • Cash and cash equivalents totaled approximately $10 million at September 30, 2026, providing an anticipated runway into the third quarter of 2027.
  • Phase 1 trials of GTB-3650 and GTB-5550 remain ongoing, with updates expected in the fourth quarter of 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GT Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611160700PRIMZONEFULLFEED9877776) on November 16, 2026, and is solely responsible for the information contained therein.